

A)

	N	Age* (years)	Gender	Extension	Treatment	Sample type	Sample location	Mayo [†] 0/1/2/3	Duration* (years)
Group 1 (Organoid culture, microarray, qPCR, immunostaining, ISH, ELISA)									
Ctrl	11	53.5 (30-77)	8/3	-	-	6/5	0/10/1/0/0	-	-
UC	8	44.3 (37-54)	6/2	0/4/4	0/2/1/3/1/1	0/8	0/8/0/0/0	6/2/0/0	14 (8-18)
Group 2 (qPCR)									
Ctrl	13	42 (25-56)	4/9	-	-	0/13	0/13/0/0/0	-	-
UC remission	24	47 (23-71)	11/13	0/18/6	4/14/0/5/0/1	0/24	0/24/0/0/0	24/0/0/0	8.7 (0-22)
UC active	11	47 (28-71)	9/2	0/11/0	3/2/1/0/5/0	0/11	0/11/0/0/0	0/1/3/7	5.3 (0-17)
Group 3 (Immunostaining)									
Ctrl	4	57 (56-59)	2/2	-	-	4/0	0/4/0/0/0	-	-
UC remission	4	64 (55-77)	2/2	0/0/4	0/2/0/2/0/0	0/4	0/4/0/0/0	4/0/0/0	16.2 (11-29)
UC active	10	41 (21-50)	6/4	0/0/10	0/0/1/0/9/0	10/0	0/2/3/2/3	0/0/5/5	7.1 (2-14)

B)

	N	Age* (years)	Gender	Extension	Phenotype	Treatment	Sample type	Sample location	SES-CD ^{††} 0/1/2/3	Duration* (years)
Group 1 (Organoid culture, qPCR)										
Ctrl	6	55 (49-63)	4/2	-	-	-	1/5	0/6/0/0/0	-	-
CD	8	46 (19-69)	6/2	0/4/4	5/1/0/2	3/1/0/1/1/2	0/8	0/8/0/0/0	5/2/1/0	13.3 (2-36)

Supplementary Table 1. Clinical and demographic descriptions of the non-IBD controls (Ctrl) and patients with A) Ulcerative Colitis (UC) B) Crohn's Disease (CD), included in the study.

*Mean (range).

Gender: Male/Female

Extension (UC): proctitis/left-sided/pancolitis

Extension (CD): ileal/colonic/ileo-colonic

Phenotype (CD): no stricturing, no penetrating/structuring/penetrating/perianal disease

Treatment: None/Mesalazine/ Steroids/Immunosuppressants/TNF inhibitors/

Immunosuppressant+TNF inhibitors

Sample type: Surgical sample/biopsy sample

Sample location: Rectum/Sigma/Descending/Transverse/Ascending

[†] Mayo referred to the colonic segment used for the analysis

^{††} SES-CD referred to the colonic segment used for the analysis

N: number of patients included in the analysis

qPCR: quantitative real-time RT-PCR

ISH: *in situ* hybridization

ELISA: enzyme-linked immunosorbent assay